» Articles » PMID: 31391821

Adverse Reactions to Antiretroviral Therapy: a Prevalent Concern

Overview
Specialty Public Health
Date 2019 Aug 9
PMID 31391821
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The risk-benefit ratio of antiretroviral therapy (ART) is usually considered favorable due to the urgent need to control the HIV/AIDS epidemic. Current studies have shown that combined ART (two or more drugs, from two different classes) is the most effective, with benefits that go beyond clinical management of the disease playing a crucial role in preventing HIV transmission. Therefore, early identification of HIV infection followed by immediate initiation of ART has been encouraged worldwide. However, the success of this strategy has been threatened by poor engagement of patients in HIV care, which may be related to drug harms. In addition, ART is required for the life course, creating the potential for adverse drug reactions (e.g., lipodystrophies). Therefore, adverse drug reactions are a prevalent concern among people living with HIV/AIDS, even in the current era of early initiation of ART ("early ART"), with most drugs considered much safer than those used in previous eras. Accurate diagnosis, recording, and reporting, followed up with proper management and prevention, and intensive surveillance, of new and known adverse reactions to ART, should be strongly encouraged as part of the care continuum.

Citing Articles

Factors Associated With Late Antiretroviral Therapy Initiation Among People Living With HIV in Southern Iran: A Historical Cohort Study.

Afrashteh S, Fararouei M, Ghaem H, Gheibi Z Front Public Health. 2022; 10:881069.

PMID: 35784258 PMC: 9248911. DOI: 10.3389/fpubh.2022.881069.


A Challenge in Diagnosis of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome (TB-IRIS).

Suryana K HIV AIDS (Auckl). 2020; 12:263-269.

PMID: 32801925 PMC: 7398877. DOI: 10.2147/HIV.S254105.

References
1.
Bonolo P, Cesar C, Acurcio F, Ceccato M, de Padua C, Alvares J . Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS. 2005; 19 Suppl 4:S5-13. DOI: 10.1097/01.aids.0000191484.84661.2b. View

2.
Gardner E, McLees M, Steiner J, Del Rio C, Burman W . The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011; 52(6):793-800. PMC: 3106261. DOI: 10.1093/cid/ciq243. View

3.
Jaquet A, Mama Djima M, Coffie P, Kacou H, Eholie S, Messou E . Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire. Pharmacoepidemiol Drug Saf. 2011; 20(12):1303-10. PMC: 3227553. DOI: 10.1002/pds.2182. View

4.
Wilson G, Wolff M . [A decade of antiretroviral therapy: a profile of patients with 10 years of highly effective triple therapy]. Rev Chilena Infectol. 2012; 29(3):337-43. DOI: 10.4067/S0716-10182012000300015. View

5.
de Waal R, Cohen K, Maartens G . Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One. 2013; 8(5):e63623. PMC: 3665842. DOI: 10.1371/journal.pone.0063623. View